The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Open accessAbstract
Background Chimeric antigen receptor (CAR) modified T cells targeting CD19 have shown activity in case series of patients with acute and chronic lymphocytic leukaemia and B-cell lymphomas, but feasibility, toxicity, and response rates of consecutively enrolled patients treated with a consistent regimen and assessed on an intention-to-treat basis have not been reported. We aimed to define feasibility, toxicity, maximum tolerated dose, response rate, and biological correlates of response in children and young adults with refractory B-cell malignancies treated with CD19-CAR T cells. Methods This phase 1, dose-escalation trial consecutively enrolled children and young adults (aged 1-30 years) with relapsed or refractory acute lymphoblastic leukaemia or non-Hodgkin lymphoma. Autologous T cells were engineered via an 11-day manufacturing process to express a CD19-CAR incorporating an anti-CD19 single-chain variable fragment plus TCR zeta and CD28 signalling domains. All patients received fludarabine and cyclophosphamide before a single infusion of CD19-CAR T cells. Using a standard 3 + 3 design to establish the maximum tolerated dose, patients received either 1 × 10(6) CAR-transduced T cells per kg (dose 1), 3 × 10(6) CAR-transduced T cells per kg (dose 2), or the entire CAR T-cell product if sufficient numbers of cells to meet the assigned dose were not generated. After the dose-escalation phase, an expansion cohort was treated at the maximum tolerated dose. The trial is registered with ClinicalTrials.gov, number NCT01593696. Findings Between July 2, 2012, and June 20, 2014, 21 patients (including eight who had previously undergone allogeneic haematopoietic stem-cell transplantation) were enrolled and infused with CD19-CAR T cells. 19 received the prescribed dose of CD19-CAR T cells, whereas the assigned dose concentration could not be generated for two patients (90% feasible). All patients enrolled were assessed for response. The maximum tolerated dose was defined as 1 × 10(6) CD19-CAR T cells per kg. All toxicities were fully reversible, with the most severe being grade 4 cytokine release syndrome that occurred in three (14%) of 21 patients (95% CI 3·0-36·3). The most common non-haematological grade 3 adverse events were fever (nine [43%] of 21 patients), hypokalaemia (nine [43%] of 21 patients), fever and neutropenia (eight [38%] of 21 patients), and cytokine release syndrome (three [14%) of 21 patients). Interpretation CD19-CAR T cell therapy is feasible, safe, and mediates potent anti-leukaemic activity in children and young adults with chemotherapy-resistant B-precursor acute lymphoblastic leukaemia. All toxicities were reversible and prolonged B-cell aplasia did not occur. Funding National Institutes of Health Intramural funds and St Baldrick's Foundation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“All approved CAR T-cell products are second-generation CARs that incorporate CD28 or CD137 (4-1BB) co-stimulatory signals, which are essential for eliciting effector and memory cell expansion and persistence and a clinically relevant immune response (9-15).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Further, most clinical protocols, and all the commercially approved therapies, have relied on viral vectors to deliver CAR transgenes into T cells (9-14,24-26).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“First, most CAR T cell trials to date have used autologous peripheral blood and apheresis as the main cell sources for manufacturing (9-18,21,22).”
From Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy (2021) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 4,694
Revised response criteria for malignant lymphoma.
Cheson, B. D., Pfistner, B., Juweid, M., Gascoyne, R., Specht, L., Horning, S., Coiffier, B., Fisher, R. I., Hagenbeek, A., Zucca, E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.2403 · Cited by 4,537
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200318921 · Cited by 3,436
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Self-citationMorgan, R. A., Yang, J. C.-H., Kitano, M., Dudley, M. E., Laurençot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,564
Self-citationEfficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Kalos, M. D., Levine, B. L., Porter, D. L., Katz, S. I., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,417
Brentjens, R. J., Davila, M. L., Riviere, I., Park, J., Wang, X., Cowell, L. G., Bartido, S., Stefanski, J., Taylor, C., Olszewska, M., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005930 · Cited by 2,063
Cited by
Sorted by citations
Items 501–600 of 1,006
Akahori, Y., Wang, L., Yoneyama, M., Seo, N., Okumura, S., Miyahara, Y., Amaishi, Y., Okamoto, S., Mineno, J., Ikeda, H., et al. (2018) · Blood · doi:10.1182/blood-2017-08-802926 · Cited by 109
Effect of cryopreservation on autologous chimeric antigen receptor T cell characteristics
Panch, S. R., Srivastava, S. K., Elavia, N., McManus, A., Liu, S., Jin, P., Highfill, S. L., Li, X., Dagur, P., Kochenderfer, J. N., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.05.015 · Cited by 107
Self-citationLi, W., Guo, L., Rathi, P., Marinova, E., Gao, X., Wu, M.-F., Liu, H., Dotti, G., Gottschalk, S. M., Metelitsa, L. S., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.025 · Cited by 109
Kansagra, A. J., Frey, N. V., Bar, M., Laetsch, T. W., Carpenter, P. A., Savani, B. N., Heslop, H. E., Bollard, C. M., Komanduri, K. V., Gastineau, D. A., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.12.068 · Cited by 110
Self-citationManagement of cytokine release syndrome related to CAR-T cell therapy
Chen, H., Wang, F., Zhang, P., Zhang, Y., Chen, Y., Fan, X.-H., Cao, X.-M., Liu, J., Yang, Y., Wang, B., et al. (2019) · Frontiers of Medicine · doi:10.1007/s11684-019-0714-8 · Cited by 113
Zhu, Z., Liu, W., & Gotlieb, V. K. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.12.002 · Cited by 109
Bader, P., Salzmann‐Manrique, E., Balduzzi, A., Dalle, J., Woolfrey, A. E., Bar, M., Verneris, M. R., Borowitz, M. J., Shah, N. N., Gossai, N. P., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000449 · Cited by 107
Self-citationYap suppresses T-cell function and infiltration in the tumor microenvironment
Stampouloglou, E., Cheng, N., Federico, A. N., Slaby, E. M., Monti, S., Szeto, G. L., & Varelas, X. (2020) · PLoS Biology · doi:10.1371/journal.pbio.3000591 · Cited by 108
Si, S., & Teachey, D. T. (2020) · PubMed Central · doi:10.2147/tcrm.s223468 · Cited by 108
Meyran, D., Zhu, J. J., Butler, J., Tantalo, D. G. M., Macdonald, S., Nguyen, T. N., Wang, M., Thio, N., D’Souza, C., Qin, V. M., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abk1900 · Cited by 108
Evolution to plasmablastic lymphoma evades CD19‐directed chimeric antigen receptor T cells
Evans, A. G., Rothberg, P. G., Burack, R., Huntington, S. F., Porter, D. L., Friedberg, J. W., & Liesveld, J. L. (2015) · British Journal of Haematology · doi:10.1111/bjh.13562 · Cited by 105
Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor
Fisher, J. P. H., Abramowski, P., Don, N. D. W., Flutter, B. R., Capsomidis, A., Cheung, G. W.-K., Gustafsson, K. T., & Anderson, J. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.002 · Cited by 106
Cytokine release syndrome: Who is at risk and how to treat
Frey, N. V. (2017) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2017.09.002 · Cited by 106
The Pharmacology of T Cell Therapies
Milone, M. C., & Bhoj, V. G. (2018) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2018.01.010 · Cited by 103
The role of long non-coding RNA GAS5 in cancers
Ji, J., Dai, X., Yeung, S. J., & He, X. (2019) · Cancer Management and Research · doi:10.2147/cmar.s189052 · Cited by 105
Sanber, K. S., Savani, B. N., & Jain, T. (2021) · British Journal of Haematology · doi:10.1111/bjh.17544 · Cited by 111
Wang, T., Tang, Y., Cai, J., Wan, X., Hu, S., Lu, X., Xie, Z., Qiao, X., Jiang, H., Shao, J., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01214 · Cited by 113
Larson, S. M., Walthers, C. M., Ji, B., Ghafouri, S. N., Naparstek, J., Trent, J., Chen, J. M., Roshandell, M., Harris, C. M., Khericha, M., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0964 · Cited by 111
Kailayangiri, S., Altvater, B., Spurny, C., Jamitzky, S., Schelhaas, S., Jacobs, A. H., Wiek, C., Roellecke, K., Hanenberg, H., Hartmann, W., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1250050 · Cited by 104
Challenges and opportunities of allogeneic donor-derived CAR T cells
Yang, Y., Jacoby, E., & Fry, T. J. (2015) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000181 · Cited by 101
Self-citationSiegler, E. L., Kim, K. G., Chen, X., Siriwon, N., Mac, J., Rohrs, J. A., Bryson, P. D., & Wang, P. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.08.010 · Cited by 104
Mamonkin, M., Mukherjee, M., Srinivasan, M., Sharma, S., Gomes‐Silva, D., Mo, F., Krenciute, G., Orange, J. S., & Brenner, M. K. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0126 · Cited by 106
Pediatric Cancer Immunotherapy: Opportunities and Challenges
Wedekind, M. F., Denton, N. L., Chen, C., & Cripe, T. P. (2018) · Pediatric Drugs · doi:10.1007/s40272-018-0297-x · Cited by 113
Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy
Zhang, E., Yang, P., Gu, J., Wu, H., Chi, X., Liu, C., Wang, Y., Xue, J., Qi, W., Sun, Q., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0646-9 · Cited by 109
Neurologic Complications after Allogeneic Hematopoietic Stem Cell Transplantation
Maffini, E., Festuccia, M. B., Brunello, L., Boccadoro, M., Giaccone, L., & Bruno, B. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.12.632 · Cited by 103
CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond
Chang, Z., & Chen, Y. Y. (2017) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2017.03.002 · Cited by 105
Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells
Lai, Y., Weng, J., Wei, X., Qin, L., Lai, P., Zhao, R., Jiang, Z., Li, B., Lin, S., Wang, S., et al. (2017) · Leukemia · doi:10.1038/leu.2017.249 · Cited by 105
Hoffmann, J., Schubert, M., Wang, L., Hückelhoven, A. G., Sellner, L., Stock, S., Schmitt, A., Kleist, C., Gern, U., Loskog, A., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01956 · Cited by 107
Towards Immunotherapy for Pediatric Brain Tumors
Wang, S. S., Bandopadhayay, P., & Jenkins, M. R. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.05.009 · Cited by 104
Wang, Y., Qi, K., Cheng, H., Cao, J., Shi, M., Qiao, J., Yan, Z., Jing, G., Pan, B., Sang, W., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.11.027 · Cited by 105
Gu, R., Liu, F., Zou, D., Xu, Y., Yang, L., Liu, B., Liu, W., Chen, X., Liu, K., Guo, Y., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00953-8 · Cited by 104
Model‐Based Cellular Kinetic Analysis of Chimeric Antigen Receptor‐T Cells in Humans
Liu, C., Ayyar, V. S., Zheng, X., Chen, W., Zheng, S., Mody, H. R., Wang, W., Heald, D., Singh, A. P., & Cao, Y. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2040 · Cited by 102
CAR-T Cell Therapy: From the Shop to Cancer Therapy
Uscanga‐Palomeque, A. C., Chávez-Escamilla, A. K., Alvizo-Báez, C. A., Saavedra-Alonso, S., Terrazas-Armendáriz, L. D., Támez-Guerra, R., Rodrı́guez-Padilla, C., & Alcocer-González, J. M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242115688 · Cited by 116
State of the art in CAR T cell therapy for CD19+ B cell malignancies
Frigault, M. J., & Maus, M. V. (2020) · Journal of Clinical Investigation · doi:10.1172/jci129208 · Cited by 107
Brüggemann, M., & Kotrová, M. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017009845 · Cited by 100
Adoptive T cell therapy: An overview of obstacles and opportunities
Baruch, E. N., Berg, A. L., Besser, M. J., Schachter, J., & Markel, G. (2017) · Cancer · doi:10.1002/cncr.30491 · Cited by 104
Dawson, N. A. J., Lamarche, C., Hoeppli, R. E., Bergqvist, P. J., Fung, V. C. W., McIver, E., Huang, Q. B., Gillies, J. K., Speck, M., Orban, P. C., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123672 · Cited by 99
Shalabi, H., Sachdev, V., Kulshreshtha, A., Cohen, J. W., Yates, B., Rosing, D. R., Sidenko, S., Delbrook, C., Mackall, C. L., Wiley, B. M., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001159 · Cited by 102
Self-citationRewiring mitochondrial metabolism to counteract exhaustion of CAR-T cells
Huang, Y., Si, X., Shao, M., Teng, X., Xiao, G., & Huang, H. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01255-x · Cited by 110
Geyer, M. B., Rivière, I., Sénéchal, B., Wang, X., Wang, Y., Purdon, T. J., Hsu, M., Devlin, S. M., Palomba, M. L., Halton, E. F., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.122627 · Cited by 100
Cardiotoxicity from chimeric antigen receptor-T cell therapy for advanced malignancies
Totzeck, M., Michel, L., Lin, Y., Herrmann, J., & Rassaf, T. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac106 · Cited by 103
Liu, B., Zou, F., Lu, L., Chen, C., He, D., Zhang, X., Tang, X., Liu, C., Li, L., & Zhang, H. (2016) · Journal of Virology · doi:10.1128/jvi.00852-16 · Cited by 101
Self-citationTasian, S. K., & Hunger, S. P. (2016) · British Journal of Haematology · doi:10.1111/bjh.14474 · Cited by 101
Makita, S., Yoshimura, K., & Tobinai, K. (2017) · Cancer Science · doi:10.1111/cas.13239 · Cited by 107
Gauthier, J., & Yakoub‐Agha, I. (2017) · Current Research in Translational Medicine · doi:10.1016/j.retram.2017.08.003 · Cited by 107
Acharya, U. H., Dhawale, T. M., Yun, S., Jacobson, C. A., Chávez, J. C., Ramos, J., Appelbaum, J., & Maloney, D. G. (2019) · Expert Review of Hematology · doi:10.1080/17474086.2019.1585238 · Cited by 102
Bispecific Antibodies in Multiple Myeloma: Present and Future
Lancman, G., Sastow, D. L., Cho, H. J., Jagannath, S., Madduri, D., Parekh, S. S., Richard, S., Richter, J. R., Sanchez, L. J., & Chari, A. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0028 · Cited by 106
Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist
Maus, M. V., & Levine, B. L. (2016) · The Oncologist · doi:10.1634/theoncologist.2015-0421 · Cited by 99
Castillo, J. J., Beltrán, B., Miranda, R. N., Young, K. H., Chávez, J. C., & Sotomayor, E. M. (2018) · American Journal of Hematology · doi:10.1002/ajh.25112 · Cited by 98
New Approaches to the Management of Adult Acute Lymphoblastic Leukemia
Bassan, R., Bourquin, J., DeAngelo, D. J., & Chiaretti, S. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.3648 · Cited by 100
Locatelli, F., Zugmaier, G., Mergen, N., Bader, P., Jeha, S., Schlegel, P., Bourquin, J., Handgretinger, R., Brethon, B., Rössig, C., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00342-x · Cited by 98
NOT-Gated CD93 CAR T Cells Effectively Target AML with Minimized Endothelial Cross-Reactivity
Richards, R. M., Zhao, F., Freitas, K. A., Parker, K. R., Xu, P., Fan, A. C., Sotillo, E., Daugaard, M., Oo, H. Z., Liu, J., et al. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0208 · Cited by 97
Self-citationT Cell Fitness and Autologous CAR T Cell Therapy in Haematologic Malignancy
Mehta, P. H., Fiorenza, S., Koldej, R. M., Jaworowski, A., Ritchie, D. S., & Quinn, K. M. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.780442 · Cited by 99
Huarte, E., O’Connor, R. S., Peel, M. T., Nuñez-Cruz, S., Leferovich, J. M., Juvekar, A., Yang, Y., Truong, L., Huang, T., Naim, A. B., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1739 · Cited by 102
Lee, Y. G., Guruprasad, P., Ghilardi, G., Pajarillo, R., Sauter, C. T., Patel, R. P., Ballard, H. J., Hong, S. J., Chun, I., Yang, N., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1026 · Cited by 102
Chimeric antigen receptor T ( CAR‐T ) cells: Novel cell therapy for hematological malignancies
Abbasi, S., Totmaj, M. A., Abbasi, M., Hajazimian, S., Goleij, P., Behroozi, J., Shademan, B., Isazadeh, A., & Baradaran, B. (2022) · Cancer Medicine · doi:10.1002/cam4.5551 · Cited by 104
Feldman, S. A., Assadipour, Y., Kriley, I. R., Goff, S. L., & Rosenberg, S. A. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.005 · Cited by 100
Self-citationMa, Q., Garber, H. R., Lu, S., He, H., Tallis, E., Ding, X., Сергеева, А., Wood, M. S., Dotti, G., Salvado, B., et al. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.05.001 · Cited by 96
Frishman‐Levy, L., & Izraeli, S. (2016) · British Journal of Haematology · doi:10.1111/bjh.14411 · Cited by 102
Ceppi, F., Rivers, J. M., Annesley, C., Pinto, N. R., Park, J. R., Lindgren, C. G., Mgebroff, S., Linn, N., Delaney, M., & Gardner, R. A. (2018) · Transfusion · doi:10.1111/trf.14569 · Cited by 96
Zhang, R., Wei, D., Liu, Z.-K., Yong, Y., Wei, W., Zhang, Z., Lv, J., Zhang, Z., Chen, Z., & Bian, H. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00233 · Cited by 95
Yang, Y., Badeti, S., Hsiang-Chi, T., Ma, M. T., Liu, T., Jiang, J., Liu, C., & Liu, D. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.014 · Cited by 96
Kong, W., Dimitri, A. J., Wenliang, W., Jung, I.-Y., Ott, C. J., Fasolino, M., Wang, Y., Kulikovskaya, I. M., Gupta, M., Yoder, T., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145459 · Cited by 99
Disruption of SUV39H1 -Mediated H3K9 Methylation Sustains CAR T-cell Function
Jain, N., Zhao, Z., Koche, R. P., Antelope, C., Gozlan, Y., Montalbano, A., Brocks, D., Lopez, M., Dobrin, A., Shi, Y., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1319 · Cited by 95
CRISPR-mediated genome editing and human diseases
Cai, L., Fisher, A. L., Huang, H., & Xie, Z. (2016) · Genes & Diseases · doi:10.1016/j.gendis.2016.07.003 · Cited by 83
Gore, L., Ivy, S. P., Balis, F. M., Rubin, E. H., Thornton, K. A., Donoghue, M. B., Roberts, S. A., Bruinooge, S. S., Ersek, J. L., Goodman, N., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.4144 · Cited by 95
Rice, J., Nagle, S. J., Randall, J., & Hinson, H. E. (2019) · Current Treatment Options in Neurology · doi:10.1007/s11940-019-0580-3 · Cited by 94
CAR-T cells: Early successes in blood cancer and challenges in solid tumors
Dana, H., Chalbatani, G. M., Jalali, S. A., Mirzaei, H. R., Grupp, S. A., Suarez, E. R., Rapôso, C., & Webster, T. J. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.10.020 · Cited by 100
Neurological updates: neurological complications of CAR-T therapy
Tallantyre, E. C., Evans, N. A., Parry-Jones, J., Morgan, M. P. G., Jones, C. H., & Ingram, W. A. (2020) · Journal of Neurology · doi:10.1007/s00415-020-10237-3 · Cited by 100
Tocchetti, C. G., Farmakis, D. T., Koop, Y., Andrés, M. S., Couch, L. S., Formisano, L., Ciardiello, F., Pane, F., Au, L., Emmerich, M., et al. (2024) · European Journal of Heart Failure · doi:10.1002/ejhf.3340 · Cited by 102
Nagel, I., Bartels, M., Duell, J., Oberg, H., Ussat, S., Bruckmueller, H., Ottmann, O. G., Pfeifer, H., Trautmann, H., Gökbuget, N., et al. (2017) · Blood · doi:10.1182/blood-2017-05-782888 · Cited by 97
Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side
Hudecek, M., Izsvák, Z., Johnen, S., Renner, M., Thumann, G., & Ivics, Z. (2017) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2017.1304354 · Cited by 99
Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective
Rivière, I., & Sadelain, M. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.03.034 · Cited by 96
Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia
Wei, G., Wang, J., Huang, H., & Zhao, Y. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0516-x · Cited by 93
Zheng, P., Li, J., & Kros, J. M. (2017) · Medicinal Research Reviews · doi:10.1002/med.21463 · Cited by 101
A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy
Epperly, R., Gottschalk, S. M., & Velasquez, M. P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00262 · Cited by 98
Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines
Lohmueller, J. J., & Finn, O. J. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.03.008 · Cited by 96
Zhi, C., Wei, R., Ma, Q., Shi, L., He, F., Shi, Z., Jin, T., Xie, R., Wei, B., Chen, J., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.022 · Cited by 94
Determinants of response and resistance to CAR T cell therapy
Lesch, S., Benmebarek, M.-R., Cadilha, B. L., Stoiber, S., Subklewe, M. S., Endres, S., & Kobold, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.004 · Cited by 96
Overcoming Antigen Escape with CAR T-cell Therapy
Jackson, H. J., & Brentjens, R. J. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1275 · Cited by 96
Immune-based therapies for childhood cancer
Mackall, C. L., Merchant, M. S., & Fry, T. J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.177 · Cited by 93
Self-citationReview: Current clinical applications of chimeric antigen receptor (CAR) modified T cells
Geyer, M. B., & Brentjens, R. J. (2016) · Cytotherapy · doi:10.1016/j.jcyt.2016.07.003 · Cited by 96
Tang, X.-Y., Sun, Y., Zhang, A., Hu, G., Cao, W. W., Wang, D., Zhang, B., & Chen, H. (2016) · BMJ Open · doi:10.1136/bmjopen-2016-013904 · Cited by 95
Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
Fan, M., Li, M., Gao, L., Geng, S., Wang, J., Wang, Y., Yan, Z., & Yu, L. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0519-7 · Cited by 97
Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy
Rashdan, S., Minna, J. D., & Gerber, D. E. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30172-3 · Cited by 93
A highly soluble Sleeping Beauty transposase improves control of gene insertion
Querques, I., Mades, A., Zuliani, C., Miskey, C., Alb, M., Grueso, E., Machwirth, M., Rausch, T., Einsele, H., Ivics, Z., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0291-z · Cited by 93
Yan, Z., Zhang, H.-X., Cao, J., Zhang, C., Liu, H., Huang, H., Cheng, H., Qiao, J., Wang, Y., Wang, Y., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.611366 · Cited by 93
Self-citationA BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers
Wong, D. P., Roy, N. K., Zhang, K., Anukanth, A., Asthana, A., Shirkey, N. J., Dunmire, S. K., Jones, B. J., Lahr, W. S., Webber, B. R., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27853-w · Cited by 94
Raikar, S. S., Fleischer, L. C., Moot, R., Fedanov, A., Paik, N. Y., Knight, K. A., Doering, C. B., & Spencer, H. T. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1407898 · Cited by 92
Castillo, J. J., Beltrán, B., Miranda, R. N., Young, K. H., Chávez, J. C., & Sotomayor, E. M. (2016) · American Journal of Hematology · doi:10.1002/ajh.24370 · Cited by 91
Posttransplant chimeric antigen receptor therapy
Smith, M. M., Zakrzewski, J. L., James, S. E., & Sadelain, M. (2018) · Blood · doi:10.1182/blood-2017-08-752121 · Cited by 93
Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy
Pang, Y., Hou, X., Yang, C., Liu, Y., & Jiang, G. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0840-y · Cited by 95
Chou, C. K., & Turtle, C. J. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1729735 · Cited by 92
Dekker, L., Calkoen, F., Jiang, Y., Blok, H., Veldkamp, S. R., de Koning, C. C. H., Spoon, M., Admiraal, R., Hoogerbrugge, P. M., Vormoor, B. J., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2021006700 · Cited by 91
Immunotherapy approaches in the treatment of malignant brain tumors
Dunn‐Pirio, A., & Vlahovic, G. (2016) · Cancer · doi:10.1002/cncr.30371 · Cited by 91
Yu, W., & Hua, Z. (2019) · Cancers · doi:10.3390/cancers11010047 · Cited by 92
Engineering advanced cancer therapies with synthetic biology
Wu, M.-R., Jusiak, B., & Lu, T. K. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0121-0 · Cited by 96
Determinants of Response and Mechanisms of Resistance of CAR T-cell Therapy in Multiple Myeloma
van de Donk, N. W. C. J., Themeli, M., & Usmani, S. Z. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-20-0227 · Cited by 90
Li, X., Shao, M., Zeng, X., Qian, P., & Huang, H. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00764-4 · Cited by 94
Present and Future of Allogeneic Natural Killer Cell Therapy
Lim, O., Jung, M. Y., Hwang, Y. K., & Shin, E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00286 · Cited by 89
Metadata
- Authors
- Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., Steinberg, S. M., Stroncek, D., Tschernia, N., Yuan, C., Zhang, H., Zhang, L., Rosenberg, S. A., Wayne, A. S., & Mackall, C. L.
- Affiliations
- National Institutes of Health (US)
- National Cancer Institute (US)
- University of Nevada, Reno (US)
- University of Southern California (US)
- Corresponding author
- Mackall, Crystal L
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2015-02
- Volume
- 385
- Issue
- 9967
- Pages
- 517-528
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC7065359
- OpenAlex
- W2129702476
- Cited by
- 2,898
- References
- 37
- Citations by year
- 2026: 86 · 2025: 154 · 2024: 175 · 2023: 217 · 2022: 275 · 2021: 311 · 2020: 350 · 2019: 317 · 2018: 315 · 2017: 314 · 2016: 232 · 2015: 134
- FWCI
- 103.68
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- St. Baldrick's Foundation
- Entertainment Industry Foundation
- National Institutes of Health
- National Cancer Institute (Z01BC011072, Z01BC010566, Z01BC011024)
- National Institute of Allergy and Infectious Diseases
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Health Sciences › Medicine › Hematology › Acute Lymphoblastic Leukemia research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CD19 chimeric antigen receptor, CAR T-cell therapy, acute lymphoblastic leukemia, non-Hodgkin lymphoma, relapsed or refractory B-cell malignancies, maximum tolerated dose, cytokine release syndrome, neurotoxicity, non-relapse mortality, fludarabine and cyclophosphamide conditioning
- MeSH terms
- Adolescent, Adult, Child, Child, Preschool, Chimera, Feasibility Studies, Female, Humans, Infant, Lymphoma, Non-Hodgkin, Male, Receptors, Antigen, T-Cell, T-Lymphocytes, Cohort Studies, Treatment Outcome, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Cell- and Tissue-Based Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
